Ph.D., HDR, Team Leader
Cancer Research Ctr of Toulouse/Inserm/CNRS/University of Toulouse III
Toulouse Cedex 1, Midi-Pyrenees, France
Dr Marc Poirot is a first class research director at the French National Institute of Health and Medical Research. Marc Poirot lead the team INOV :”Cholesterol metabolism and therapeutic innovations” with his long-time collaborator Dr Sandrine Silvente-Poirot at the Cancer Research Center of Toulouse, France at the Cancer Research Center of Toulouse (France). Marc studied organic chemistry and biochemistry at the university Paul Sabatier of Toulouse where he received his PhD degree on chemical biology, working under the supervision of Jean-Charles Faye. He did a post-doc at Sanofi-Elf-bio-recherche and get tenured at Inserm (French NIH) as a research scientist. Marc was next visiting scientist at the National Institute of Health (NIH, Bethesda, MD, USA) to work on steroid hormone receptors. His research interests include studies on cholesterol metabolism deregulations in cancers. With Sandrine and their team, they identified new bioactive cholesterol metabolites highlighting the existence of a new branch on the cholesterol metabolic pathway. This branch is centered on 5,6-epoxycholesterols (5,6-EC) which they showed to be differentially metabolized in cancer cells compared to normal cells. They found that in tumors 5,6-EC are transformed into oncosterone an oncometabolite with tumor promoter properties. Alternatively, in normal tissue, they showed that 5,6α-EC is enzymatically conjugated to histamine to give dendrogenin A, which displays tumor suppressor properties. Dendrogenin A was actually the first steroidal alkaloid identified in mammals. Marc’s group is identifying new mammalian sterol metabolites, their biosynthesis enzymes, characterized their biological properties and their mechanism of action. Marc published more than 130 scientific articles/reviews/patentsand and sit on the editorial board of Journal of Steroid Biochemistry and Molecular Biology, Steroids, and Biochemical Pharmacology.
Disclosure information not submitted.
Tuesday, May 2, 2023
2:30 PM – 3:10 PM MDT